Form 4: Vera Therapeutics Executive Granted Equity Awards

Joseph R. Young, SVP of Finance and Chief Accounting Officer at Vera Therapeutics, received 10,000 restricted stock units and options for 20,000 shares.

Summary

• Joseph R. Young, SVP, Finance, Chief Accounting Officer of Vera Therapeutics, Inc. (VERA), was granted equity awards.
• On February 4, 2026, Young acquired 10,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments, starting on February 20, 2027, and continuing through 2030, contingent on continuous service.
• Additionally, on February 4, 2026, Young was granted stock options for 20,000 shares of Class A Common Stock with an exercise price of $42.74.
• These stock options will vest at a rate of 1/48th of the shares monthly, beginning March 4, 2026, also subject to continuous service, and expire on February 3, 2036.
• Following these transactions, Young directly beneficially owns 67,839 shares of Class A Common Stock and 20,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance and shareholder value.

Positives

• The grant of equity awards to a key executive (SVP, Finance, Chief Accounting Officer) aligns management's interests with shareholders.
• The awards include both RSUs and stock options, providing a mix of retention and performance incentives.
• The multi-year vesting schedules encourage long-term commitment and continuous service from the executive.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continuous service, meaning the awards could be forfeited if employment terminates.
• The value of the stock options is dependent on the future market price of Vera Therapeutics' Class A Common Stock exceeding the exercise price of $42.74.

Future Outlook

The filing indicates a long-term incentive structure for a key executive, with vesting schedules extending through 2030 for RSUs and options expiring in 2036, suggesting an expectation of continued service and future company performance.

Industry Context

StockSavvy.ai notes that equity grants to senior executives are a standard practice across the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate key talent by aligning their financial interests with long-term shareholder value creation. Such grants are particularly common in growth-oriented companies like Vera Therapeutics, where future success is heavily dependent on executive leadership and innovation.

Comparison to Industry Standards

• The grant of both RSUs and stock options is a common hybrid approach in executive compensation, similar to practices at biotech peers such as Moderna or BioNTech, which often use a mix of time-based and performance-based equity.
• The multi-year vesting schedule (4 years for RSUs, 48 months for options) is standard for executive retention, comparable to vesting schedules seen at companies like Gilead Sciences or Amgen for similar roles.
• The exercise price of $42.74 for the stock options is set at the market price on the grant date, which is a typical practice to ensure options provide value only if the stock price appreciates, aligning with shareholder interests.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive interests with long-term stock performance. Dilution from future RSU settlement and option exercise is a consideration, but this is standard for equity compensation.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.

Next Steps

• Continued service of Joseph R. Young to ensure vesting of equity awards.
• Future vesting dates for RSUs on February 20, 2027, 2028, 2029, and 2030.
• Monthly vesting of stock options beginning March 4, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a senior executive, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Vera Therapeutics, VERA, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Joseph R. Young, SVP Finance, Chief Accounting Officer